Welcome to our dedicated page for Savara news (Ticker: SVRA), a resource for investors and traders seeking the latest updates and insights on Savara stock.
Savara Inc. (symbol: SVRA) is a specialty biopharmaceutical company that focuses on developing innovative therapies for rare respiratory diseases. The company’s principal approach centers on addressing serious and life-threatening pulmonary conditions. Its flagship product, AeroVanc, is the first-ever dry powder inhaled antibiotic specifically designed to treat methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis (CF). This groundbreaking treatment aims to improve the quality of life and health outcomes for these patients.
Another significant project by Savara is the molgramostim nebulizer solution (molgramostim). This is an inhaled granulocyte-macrophage colony-stimulating factor currently in Phase 3 development for treating autoimmune pulmonary alveolar proteinosis (aPAP). aPAP is a rare and often debilitating lung disease with limited treatment options, and molgramostim seeks to fill this critical gap.
Savara's dedication to addressing unmet medical needs is evident through its focused development pipeline. The company operates as a single-segment entity specializing in respiratory system pharmaceuticals, highlighting its concentrated expertise and commitment to improving respiratory health.
In terms of financial health and partnerships, Savara has made strategic moves to secure funding and collaborations that bolster its research and development efforts. These partnerships and financial strategies are crucial for advancing its clinical programs and bringing innovative treatments to market.
For more detailed information on the company and its projects, please visit Savara’s official websites at www.savarapharma.com and www.aerovanc.com.
Savara Inc. (NASDAQ: SVRA), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The management team will present on January 10, 2022, at 7:00 AM ET. A webcast of the presentation will be accessible on Savara’s website and archived for 90 days. The company focuses on rare respiratory diseases, with its lead program, molgramostim nebulizer solution, in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company, announced the grant of inducement awards to five new employees on December 1, 2021. The awards consist of options to purchase a total of 280,000 shares of common stock at an exercise price of $1.08 per share, matching the closing price on the grant date. These options have a 10-year term and vest quarterly. Savara focuses on rare respiratory diseases, with its lead program being molgramostim nebulizer solution in Phase 3 for autoimmune pulmonary alveolar proteinosis (aPAP).
Savara Inc. (NASDAQ: SVRA), a biopharmaceutical company specializing in rare respiratory diseases, announced its participation in two upcoming healthcare conferences. The company will present a pre-recorded webcast at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, at 10:00 AM ET. Additionally, a live webcast of a fireside chat will occur during the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021, at 8:50 AM ET. The webcasts will be accessible on Savara's investor page for 90 days.
Savara Inc. (SVRA) advanced its Phase 3 IMPALA 2 trial for Molgramostim in autoimmune pulmonary alveolar proteinosis, with a 20-month enrollment timeline on track. The European Medicines Agency accepted its revised Pediatric Investigation Plan. The company ended Q3 2021 with approximately $171 million in cash, sufficient to cover operations through 2025, beyond the anticipated IMPALA-2 data readout in late Q2 2024. Financial results showed a net loss of $10.5 million, a decrease from $11.1 million in Q3 2020, and a 16.6% rise in R&D expenses due to trial progression.
Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focusing on rare respiratory diseases, will present at the Jefferies London Healthcare Conference from November 16-19, 2021. A pre-recorded, on-demand webcast of the presentation will be available starting November 18 at 3:00 am ET until November 19 at 12:00 pm ET. The replay will be accessible on Savara's Investors page for 90 days post-event. Savara's lead product, molgramostim, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Savara, a clinical stage biopharmaceutical company, announced its participation in a Fireside Chat at the inaugural Piper Sandler Lung Day on October 15, 2021, at 10:30 am ET. This event will discuss their lead program, molgramostim nebulizer solution, which is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Following the event, a replay will be available on Savara’s website for 90 days.
Savara Inc. (NASDAQ: SVRA) announced its participation in two upcoming healthcare conferences. A pre-recorded presentation for the H.C. Wainwright 23rd Annual Global Investment Conference will be available from 7:00 AM ET on September 13, 2021. Additionally, a live presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit is scheduled for 12:25 PM ET on September 20, 2021. Both presentations will be accessible on Savara's Investors page for 90 days.
Savara Inc. (Nasdaq: SVRA), a biopharmaceutical company focused on rare respiratory diseases, announced on September 2, 2021, the grant of inducement awards to two new employees. The awards consist of options to purchase 200,000 shares and restricted stock units (RSUs) covering 75,000 shares of common stock. The options have an exercise price of $1.59 per share and a 10-year term while vesting quarterly. RSUs vest in full after two years of employment. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan, per NASDAQ Listing Rules.
Savara Inc. (NASDAQ: SVRA), a biopharmaceutical company focusing on rare respiratory diseases, announced the grant of inducement awards to two new employees on August 16, 2021. These awards comprise options for 200,000 shares and restricted stock units (RSUs) for 100,000 shares, granted under the 2021 Inducement Equity Incentive Plan. The options have an exercise price of $1.19 per share and a 10-year term, with quarterly vesting. RSUs will vest fully after two years, contingent on continued employment.
Savara Inc. (NASDAQ: SVRA) reported its financial results for Q2 ending June 30, 2021. The company registered a net loss of $10.9 million or $(0.07) per share, an improvement from the $9.4 million loss or $(0.16) per share in the same quarter last year. Research and development expenses rose by 19.3% to $7.3 million, driven by the molgramostim development program. Savara's cash position stands at $181 million, with $25 million in debt. The pivotal Phase 3 IMPALA 2 trial is in progress, following successful patient dosing and site activation.
FAQ
What is the current stock price of Savara (SVRA)?
What is the market cap of Savara (SVRA)?
What does Savara Inc. specialize in?
What is AeroVanc?
What is molgramostim?
What is autoimmune pulmonary alveolar proteinosis (aPAP)?
Where can I find more information about Savara Inc.?
How is Savara Inc. funded?
What is the main focus of Savara's development pipeline?
Is AeroVanc currently available on the market?
What stage is molgramostim in?
Does Savara Inc. have any other products in development?
